R&D Open Verdict? By Dr Kay Wardle As pharmaceutical companies begin to shift from in-house R&D to external partnerships and 'open innovation', the traditional drug discovery model may soon be a thing of the past. In this article we explain what is driving these changes and what the implications are for the R&D workforce. The [...]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!